Trial Profile
A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Newly Diagnosed Wet Age-Related Macular Degeneration (wAMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Lazucirnon (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Alkahest
- 01 Jun 2022 Results published in the Retina
- 25 Mar 2019 Results published in the Media Release
- 25 Mar 2019 According to an Alkahest media release, data from this study presented as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress.